我要投票 Sanchine三精在补钙行业中的票数:8
· 外 推 电 报 ·
2024-11-21 21:00:56 星期四

【Sanchine三精是哪个国家的品牌?】

Sanchine三精是什么牌子?「Sanchine三精」是 哈药集团三精制药有限公司 旗下著名品牌。该品牌发源于黑龙江,由创始人芦传有在2015期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

三精制药始建于1950年,初期以生产肌肉和静脉水针剂为主,是黑龙江省最早的专业化生产水针剂和国内最早引进国外水针剂一连机生产设备的企业,是最早通过国家GMP认证的医药企业之一。公司现总占地面积110万平方米,员工总数近6000人,是以OTC产品、处方药与保健食品为主、医药原料和制剂并重的综合性制药企业。2004年,“三精”品牌被国家工商总局认定为“驰名保护”。2011年5月13日,“三精”品牌在“2011中国最有价值品牌评价”中,经权威机构认定,品牌价值为68.93亿元人民币。

目前,三精制药拥有下属子公司15家,其中工业子公司8家、商业子公司5家、其他相关产业子公司2家。截至目前,公司口服液、口服溶液剂、小容量注射剂(非最终灭菌)、冻干粉针剂、片剂、粉针剂、胶囊剂、颗粒剂、合剂、糖浆剂、洗剂、茶剂、散剂13个剂型及无菌原料药(磷霉素钠、炎琥宁)、原料药(拉西地平、盐酸罗沙替丁醋酸酯)均通过2010版GMP认证。其中,口服液剂型产品年生产能力达16亿支。公司主导产品包括葡萄糖酸钙口服溶液、葡萄糖酸锌口服液、双黄连口服液、司乐平片等。近年来,通过药品、保健品的新产品立项研发,不断完善产品线,丰富产品阵容。

六十余年的制药经验,先进的技术设备,一流的管理手段,完善的科研开发体系,使“三精”牌在国内外丰享盛誉。三精一直将产品和服务视为核心竞争力,同时高度重视产品的研发,2004年建成较具规模的研发中心,已成为黑龙江省药物制剂工程技术研究中心、黑龙江省西药制剂重点实验室,承担“十一五”“重大新药创制”科技重大专项——“新型口服缓控释制剂及工艺技术平台”课题和“十二五”“重大新药创制”科技重大专项——“抗阿尔茨海默病药重酒石酸卡巴拉汀及其胶囊的研究开发”课题。2008年,公司成为“国家首批创新型企业”,2012年入选国家火炬计划重点高新技术企业。公司还先后荣获了全国质量管理先进企业、全国守合同重信用企业、全国医药系统优秀企业、全国“五·一劳动奖状”先进集体、“全国企业文化优秀成果奖”、“全国医药行业药品质量诚信建设示范企业”、“21315国际质量信用AAA++级”、“中国优秀诚信企业”、“中国化学制药行业工业企业综合实力百强”企业、黑龙江省“科技创新优秀企业奖”等荣誉称号。

英文翻译:Sanjing pharmaceutical was founded in 1950. At the early stage, it mainly produces muscle and intravenous water injection. It is the first professional enterprise in Heilongjiang Province to produce water injection and the first enterprise in China to introduce foreign water injection production equipment. It is also one of the first pharmaceutical enterprises to pass the national GMP certification. The company now covers an area of 1.1 million square meters and employs nearly 6000 people. It is a comprehensive pharmaceutical enterprise focusing on OTC products, prescription drugs and health food, with equal emphasis on pharmaceutical raw materials and preparations. In 2004, "three fine" brand was recognized as "well-known protection" by the State Administration for Industry and commerce. On May 13, 2011, in the "2011 China's most valuable brand evaluation", the brand value of "three fine" was recognized by the authority as RMB 6.893 billion. At present, Sanjing pharmaceutical has 15 subsidiaries, including 8 Industrial subsidiaries, 5 Commercial subsidiaries and 2 other related industrial subsidiaries. Up to now, 13 dosage forms of the company's oral liquid, oral solution, small volume injection (non final sterilization), freeze-dried powder injection, tablet, powder injection, capsule, granule, mixture, syrup, lotion, tea, powder, sterile API (fosfomycin sodium, Yanhuning), API (lacidipine, rosattidine hydrochloride acetate) have passed GMP certification of 2010 version. Among them, the annual production capacity of oral liquid dosage products reached 1.6 billion. The company's leading products include calcium gluconate oral solution, zinc gluconate oral solution, Shuanghuanglian oral solution, and silepin tablets. In recent years, through the research and development of new products of drugs and health products, the product line has been continuously improved and the product lineup has been enriched. With more than 60 years of pharmaceutical experience, advanced technology and equipment, first-class management means, and perfect scientific research and development system, the "three refined" brand enjoys a good reputation at home and abroad. Sanjing has always regarded products and services as its core competitiveness, and attached great importance to product research and development. In 2004, it established a relatively large-scale research and development center, which has become Heilongjiang pharmaceutical engineering and technology research center and Heilongjiang western pharmaceutical Key Laboratory, undertaking the major science and technology project of "11th Five Year plan" and "major new drug creation" -- new oral sustained and controlled release preparations and technology "Platform" project and "12th Five Year Plan" science and technology major project of "major new drug creation" - research and development of anti Alzheimer's disease drug kabalatin tartrate and its capsule ". In 2008, the company became "the first batch of national innovative enterprises", and in 2012, it was selected as a key high-tech enterprise in the national torch plan. The company has also won the national advanced quality management enterprise, the national contract abiding and trustworthy enterprise, the national excellent pharmaceutical system enterprise, the national advanced collective of "May 1st Labor Award", "national enterprise culture excellent achievement award", "national pharmaceutical industry pharmaceutical quality and integrity construction demonstration enterprise", "21315 International quality and credit AAA + + level", "China excellent and integrity enterprise" "Top 100 enterprises with comprehensive strength in China's chemical and pharmaceutical industry" and "science and technology innovation excellent enterprise award" of Heilongjiang Province, etc.

本文链接: https://www.waitui.com/brand/41c6b1011.html 联系电话:0451-86627550

千城特选小程序码

7×24h 快讯

拼多多:第三季度营收增速环比下降,将坚定高质量发展战略应对竞争挑战

36氪获悉,拼多多发布2024年第三季度财报。财报显示,本季度拼多多营收达到994亿元,与上个季度相比,营收的增速有所放缓。业内分析认为,一方面是因为电商行业的竞争依然激烈,另一方面是平台的“百亿减免”等举措影响了短期的财报表现。“为了应对行业竞争,我们将坚定地执行高质量发展战略,继续实行‘减免+扶持’的举措,持续完善平台及产业生态,为供需两侧带来更大的普惠。”拼多多陈磊表示。

2小时前

拼多多:第三季度利润环比下降22%,将长期投入“新质供给”“电商西进”战略

36氪获悉,拼多多发布2024年第三季度财报。财报显示,本季度拼多多利润达到250亿元,环比下降22%。过去这个季度,拼多多先后推出“百亿减免”“电商西进”“新质商家扶持计划”等重磅举措,持续扩大对生态建设的投资,一定程度上影响了短期的财报表现。拼多多陈磊表示,在财务数据之外,我们更加看重生态投资带来的长期价值,未来几个季度,拼多多将继续投入“新质供给”“电商西进”等战略,给用户、商家及产业带来更长远的回报。

2小时前

莎普爱思:股东拟合计减持不超5%公司股份

36氪获悉,莎普爱思公告,股东陈德康持有公司12.39%股份,上海景兴实业投资有限公司持有公司4.7%股份。陈德康计划减持公司股份数量合计不超过758.32万股,即不超过公司总股本的2%。上海景兴计划减持公司股份数量合计不超过1137.48万股,即不超过公司总股本的3%。

2小时前

永杰新材上交所主板IPO申请获证监会同意注册批复

36氪获悉,证监会下发关于同意永杰新材料股份有限公司首次公开发行股票注册的批复,同意该公司首次公开发行股票的注册申请。根据招股书,该公司拟在上交所主板上市,公司专业从事铝板带箔的研发、生产与销售,产品主要包括铝板带和铝箔两大类。

2小时前

东方电缆:公司及子公司近期中标合计约40亿元海底电缆项目

36氪获悉,东方电缆公告,公司及全资子公司东方海工院近期收到相关通知书,确认公司及东方海工院联合体为相关项目中标人。其中,直流海底电缆项目中标金额约15.14亿元,交流海底电缆项目中标金额合计约24.72亿元,以上项目合计中标金额约40亿元。同日公告,公司拟以自有资金投资建设东方中央研究院·总部项目,项目总投资金额约为5.54亿元。

2小时前

本页详细列出关于多维尔的品牌信息,含品牌所属公司介绍,多维尔所处行业的品牌地位及优势。
咨询